Vinati Organics Limited

$ 1 336.60 2.16 %

Vinati Organics Limited, established in Mumbai, India in 1989, operates as a specialty chemical enterprise specializing in the production and global distribution of organic intermediaries and monomers. While primarily serving the Indian market, the company also exports its diverse product range to key international regions including the United States, Europe, and various parts of Asia. Its extensive portfolio features a variety of specialty monomers, such as 2-acrylamido-2-methylpropane sulphonic acid (2-AMPS) and its sodium salt, alongside N-tertiary butyl acrylamide (NTBA) and N-tertiary octyl acrylamide (NTOA). The company is also a significant producer of aromatic compounds. These include isobutyl benzene, a critical precursor for manufacturing ibuprofen, an anti-inflammatory analgesic drug; normal butyl benzene, utilized in the synthesis of numerous chemical intermediates; and hexenes, valued for applications like low-boiling point solvents, thinners, extraction agents, tire retreading, as octane boosters for gasoline, and in C5/C6 aliphatic petroleum. Butyl phenols are also part of this segment. Further expanding its chemical offerings, Vinati Organics provides methyl-4-tert butyl benzoate and para tertiary butyl benzoic acid. It manufactures isobutylene, a branched olefin; methanol, which functions as a chemical intermediate; and high-purity methyl tertiary butyl ether (MTBE), widely used as a solvent in organic and pharmaceutical synthesis, as well as in Grignard's reagent production. Tertiary-butylamine is another specialized chemical produced. Additionally, the firm develops polymers tailored for diverse industrial sectors, including construction, ceramics, oil drilling, mining, leather processing, and paper manufacturing.

CEO: Vinati Saraf Mutreja - https://www.vinatiorganics.com

Price objectif

-

Recommandation

-

DCF

$ 1 713.01

Loading data...

VINATIORGA.NS vs S&P500

Loading data...

No data available.

Quick ratio

4.02

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

31.21

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

42.82

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

15.19 %

reflects reasonable profitability, showing good use of equity.

ROIC

12.03 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.17

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.00

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

22.20

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

17.57 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
20.89 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.03 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.00 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.